Celgene Corporation (CELG) Position Increased by B & T Capital Management DBA Alpha Capital Management
B & T Capital Management DBA Alpha Capital Management boosted its stake in Celgene Corporation (NASDAQ:CELG) by 4.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,778 shares of the biopharmaceutical company’s stock after buying an additional 463 shares during the period. B & T Capital Management DBA Alpha Capital Management’s holdings in Celgene Corporation were worth $1,400,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. Motco raised its stake in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the first quarter valued at approximately $118,000. Carroll Financial Associates Inc. raised its stake in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. raised its stake in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the period. Finally, Acropolis Investment Management LLC purchased a new stake in shares of Celgene Corporation during the second quarter valued at approximately $144,000. 78.16% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation (NASDAQ:CELG) opened at 134.05 on Monday. The stock has a market capitalization of $104.67 billion, a PE ratio of 50.34 and a beta of 1.89. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $135.99. The firm has a 50-day moving average of $121.46 and a 200-day moving average of $120.59.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the consensus estimate of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 EPS. On average, equities analysts expect that Celgene Corporation will post $7.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/celgene-corporation-celg-position-increased-by-b-t-capital-management-dba-alpha-capital-management/1445061.html.
Several brokerages have recently commented on CELG. Cantor Fitzgerald set a $159.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, April 27th. Leerink Swann restated a “market perform” rating on shares of Celgene Corporation in a research report on Monday, March 20th. Cann restated a “buy” rating and set a $148.00 price objective on shares of Celgene Corporation in a research report on Tuesday, April 4th. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty-two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $141.00.
In related news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James J. Loughlin sold 9,250 shares of Celgene Corporation stock in a transaction on Monday, May 1st. The stock was sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the transaction, the director now owns 32,169 shares in the company, valued at approximately $3,988,956. The disclosure for this sale can be found here. Insiders sold a total of 237,005 shares of company stock worth $31,515,142 in the last quarter. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.